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1. Introduction 
According to the American Cancer Society, 68,130 new cases of melanoma and 8,700 deaths 
were predicted for 2010 (Jemal et al., 2010). Although melanoma comprises only 5% of all 
skin cancers, it is by far the deadliest, responsible for 75% of skin cancer-related deaths, and 
its incidence is steadily increasing worldwide. Primary cutaneous melanoma has an 
excellent outcome with early surgical intervention, but regional and distant metastatic 
disease have a much more dismal prognosis. Current five-year survival rates equal 91% for 
all disease sites, including 98% for local disease, 62% for regional disease (including regional 
lymph node involvement), and only 15% for those with distant metastasis (median survival 
is only 7.5 months). Unfortunately, for those patients who will develop locally advanced 
and metastatic melanoma, current treatment options are limited in scope and effectiveness; 
thus, the overall poor mortality rates for these patients emphasize the need for better 
treatment modalities, methods of relapse prevention and earlier recognition of pre-
neoplastic and neoplastic cells (Atallah & Flaherty, 2006; Balch et al., 2001a, 2001b; Blesa et 
al., 2011).  
Currently, there are no curative therapies for metastatic melanoma. Until March 25, 2011, 
the U.S. Food and Drug Administration (FDA) had only approved two drugs for the 
treatment of metastatic melanoma, the DNA alkylating agent dacarbazine and high-dose 
Interleukin-2 (IL-2). Dacarbazine alkylates and crosslinks DNA in all phases of the cell cycle, 
impairing DNA function, inducing cell-cycle arrest and apoptosis (Bajetta et al., 2002), and is 
a common chemotherapeutic option for multiple cancers (Seam et al., 2009; Yang & 
Chapman, 2009). IL-2 activates endogenous anti-tumor-reactive T cells and natural killer 
(NK) cells. Notably, circulating NK cells from stage IV melanoma patients were recently 
shown to exhibit a unique phenotypic and functional character toward melanoma cells, and 
this unique character was altered in patients after treatment with chemotherapy (Fregni et 
al., 2011). Dacarbazine induces objective tumor regression in 15-20% of metastatic melanoma 
patients with a median survival of only 8-9 months and a 2-3% complete response rate, and 
single agent bolus IL-2, while providing a 20-30% objective response rate, creates significant 
long-term response in only 5% of patients treated, is fraught with toxicity and costly. 
Combination low-dose IL-2 and chemotherapy and single-agent high-dose IL-2 produce a 
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similarly low complete response (Atkins et al., 2000; Tsao et al., 2004). Other cytotoxic 
compounds have resulted in poor response rates and significant adverse effects, including 
temozolomide, cisplatin, carboplatin, vinca alkaloids, taxanes, and nitrosoureas (Bafaloukos 
et al., 2002; Bajetta et al., 2002; Blesa et al., 2011; Khayat et al., 2002; Middleton et al., 2000). 
Notable agents of promise currently undergoing testing are anti-CD40, anti-PD-1L, 1-MT (1-
methyl-D-tryptophan), and the BRAF-inhibitor PLX4032 (Bollag et al., 2010; Comin-Anduix; 
Flaherty et al., 2010; Fonsatti et al., 2010). On March 25, 2011, the U. S. Food and Drug 
Administration approved ipilimumab (Yervoy™, Bristol-Myers Squibb Company, New 
York, NY, USA), a monoclonal antibody against the inhibitory lymphocyte receptor, CTLA4, 
as an injection for the treatment of unresectable or metastatic melanoma (Hodi et al., 2010). 
Advanced melanomas are infamously resistant to chemotherapy, principally due to the 
presence of inherent primary anti-apoptotic and acquired cellular chemoresistance 
mechanisms (Serrone & Hersey, 1999). Of note, a recent study by Rosner et al. (Rosner et al., 
2011) described a means to circumvent such apoptosis resistance. Without activating the 
apoptosis signaling cascade or utilizing other apoptotic nucleases, recombinant 
deoxyribonuclease I (DNaseI), engineered with a nuclear localization signal and mutated 
actin-binding site to avoid entering its inactive bound form, was effective in inducing 
apoptosis in an apoptosis-resistant melanoma cell model with 70-100% killing efficiency, 
emphasizing its potential application in many of the known apoptosis-resistant cancers. 
Surgical resection of primary and known metastatic lesions is still the most effective means 
of improving overall survival of melanoma patients, though palliative care is standard for 
patients with metastases after first-line dacarbazine or other physician-preferred therapy, as 
survival is very rare (Rass et al., 2008; Tagawa et al., 2006; Yang et al., 2006). Surgery in 
partnership with radiation is standard for locoregional control, while additional chemical-, 
cell- or antibody- based therapies, or some combination thereof, are commonly attempted 
for systemic eradication of tumor cells in the blood or at unspecified sites in the body to 
combat current disease and prevent relapse and metastatic implantation. Melanoma has 
attracted a lot of interest from immunologists due to a heightened frequency over other 
solid tumors to display fast, spontaneous, complete tumor regression associated with a 
specific cellular immune response (Kadison & Morton, 2003). Chemoimmunotherapy, tumor 
vaccines and other chemotherapeutic combinations have shown improvement in objective 
response rates for melanoma patients, but they have not yet been able to show significant 
survival benefits (Bajetta et al., 2006; Eton et al., 2002; Kaufmann et al., 2005). Indeed, a 
recent meta-analysis of 18 studies comprising 2,625 participants revealed improved objective 
response rates in metastatic melanoma patients treated with chemoimmunotherapy compared 
with chemotherapy, but no improvement was noted in overall survival benefit (Sasse et al., 
2007). Additionally, hematological and non-hematological toxicities were greatest in those 
undergoing chemoimmunotherapy. 
While the historic chemoimmunotherapeutic approach has been to sensitize tumor cells to 
immunotherapy with administration of chemotherapeutic compounds, we have described a 
high degree of chemosensitization with pre-treatment of non-tumor-Ag-specific CD4+ T 
cells (Radfar et al., 2009), our termed ‘chemocentric chemoimmunotherapy’ strategy. This 
technique may provide a basis for development of novel methods of selectively reducing the 
chemoresistance of virtually all tumor cell types, given the lack of requirement for tumor-
Ag-specific T cells. We will present an overview of conventional chemoimmunotherapy 
development for melanoma and examine the functional significance of chemocentric 
chemoimmunotherapy for melanoma and other cancers. 
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2. Background 
It has long been part of the clinical canon that chemotherapy drugs negatively affect 
immunological systems, inhibiting anti-tumor immune activity by a variety of related 
mechanisms. However, the intricacies of the chemo-immuno interaction provide areas of 
opportunity for utilizing chemo drugs to enhance the immune response. These cytotoxic 
drugs tend to target dividing lymphocytes, necessary for development of an immune 
response, but they also deplete CD4+/CD25+ regulatory T cells (T reg), potentially 
enhancing the response. Again, conversely, lymphodepletion triggers homeostatic T cell 
reconstitution which proceeds to create T cells recognizing tumor as self. Opportunities arise 
during the depletion of T reg and the heightened formation of T cells, allowing an avenue to 
both infuse the patient with tumor-reactive T cells which are now not impeded by T reg and 
the potential to create within the patient a large quantity of T cells reactive to some tumor 
antigen(s).  
Conventional cancer chemotherapy is capable of inducing the death of immunologically 
sensitive tumor cells by utilizing the host innate and adaptive immune responses, e.g. 
through the induction of immunoregulatory cytokines (Bracci et al., 2007), and some of these 
drugs can alter cellular pathways of immune suppression and tolerance in a dose- and time-
dependent manner, e.g. inducing homeostatic proliferation (Bracci et al., 2007; Proietti et al., 
1998), or modulate the extracellular release of certain proteins upon cell death, e.g. HMGB1 
release and subsequent tumor survival/metastasis-promoting inflammation is inhibited by 
oxaliplatin (Dong et al., 2007). Additionally, some chemo drugs can modulate the expression 
of tumor antigens and antigen processing/presentation machinery on tumor cells. For 
example, 5-Fluorouracil (5-FU) has been shown to induce carcinoembryonic antigen (CEA) 
expression in colon and breast cancer cells (Correale et al., 2003) while 5-aza-2’-
deoxycytidine can induce the expression of cancer testis antigens and the cell surface MHC 
class I complex in melanoma and other cancers (Adair & Hogan, 2009; Coral et al., 2002; 
Fonsatti et al., 2007; Natsume et al., 2008). Notably, direct intralesional injection of the MHC 
class I complex, which allows tumor immune evasion when defective in numerous cancers 
(Lampen & van Hall, 2011; Maleno et al., 2011), via high-dose Allovectin-7® (Vical Inc., San 
Diego, CA, USA), a cationic lipid-formulated bicistronic plasmid encoding MHC-I 
components ┚-2 microglobulin and HLA-B7, in 127 recurrent or previously unresponsive to 
chemotherapy stage III and IV melanoma patients tested for efficacy in a recent phase II 
dose escalation study produced an objective response of 11.8% with median duration of 
response of 13.8 months (Bedikian et al., 2010). Tissue from two responding patients was 
noted for the absence of melanoma upon histological analysis, and the therapy was well 
tolerated.  
Drugs of complementary activity and dissimilar toxicities are routinely combined to 
enhance individual anti-tumor effects. In the 1960s, effective combination antibiotic therapy 
for tuberculosis influenced the combination treatment strategy of acute lymphocytic 
leukemia and lymphoma. A number of significant combination chemotherapeutic regimens 
were developed in the 1980s, including CVD (cisplatin, vinblastine, and dacarbazine) and 
the Dartmouth regimen (cisplatin, carmustine, dacarbazine, and tamoxifen) (Del Prete et al., 
1984; Legha et al., 1989). Notably, according to two independent clinical trials of the 1990s, 
CVD and Dartmouth were not shown to significantly increase overall survival relative to 
dacarbazine alone (Buzaid et al., 1993; Chapman et al., 1999). Although dacarbazine and 
cisplatin-based combination chemotherapy/biochemotherapy regimens combining IFN 
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and/or IL-2 are now recommended by the National Comprehensive Cancer Network 
(NCCN) Clinical Practice Guidelines in Oncology for Melanoma for stage III and IV 
melanomas, promising increases in response rates notwithstanding (Riker & Howell, 2010a, 
2010b), significant improvement in long-term responses has yet to be seen.  
Early efforts to combine chemotherapy with immunomodulators, particularly cancer 
vaccines, were discounted given the understood detrimental myelosuppressive properties of 
many chemotherapeutic compounds (Emens, 2008). This suppression was purported to be 
short-lived and reversible, as the replenishing of leukocytes following chemotherapy would 
show, by Harris et al. in 1976 (Harris et al., 1976). As reviewed by Sinkovics and Horvath 
(Sinkovics & Horvath, 2006), around this time, the M.D. Anderson Hospital Melanoma-
Sarcoma Service submitted multiple grant applications to the NCI for combination 
chemoimmunotherapeutic intervention strategies for patients with metastatic melanomas 
and sarcomas. Despite NCI rejection, clinical trials began, utilizing the findings of 
Lindenmann and Klein (Lindenmann & Klein, 1967) from nearly a decade earlier which 
showed an acquired immunity to tumor formation in mice injected with the cell culture 
lysates of oncolytic myxo- or paramyxovirus-infected tumor cells. Sinkovics et al. further 
adapted this strategy for the post-chemotherapy administration of cultured tumor cell 
lysates infected with oncolytic, attenuated PR8 influenza A virus. PR8 viral oncosylates, the 
immunotherapeutic suspension, were comprised of UV-irradiated, endotoxin-free tumor 
cell cultures with low levels of live PR8 virus. ‘Tumor-specific active immunization’ with 
viral oncosylates two-to-three weeks post-chemotherapy resulted in heightened rates of 
remission with moderate, occasionally significant increases in survival.  
Early phase clinical trials have been able to show response rates of up to 50% for 
chemoimmunotherapies (Atkins et al., 2003; Eton et al., 2002; Keilholz et al., 1997; Rosenberg 
et al., 1999); however, the duration of responses has been limited in most cases to less than a 
year. Importantly, systemic toxicities and adverse side effects tend to be heightened with 
chemoimmunotherapeutic interventions in relation to chemotherapy or immunotherapy 
alone. Furthermore, many of the most common chemotherapies were not inherently 
designed to take into account the entire tumor-host microenvironment and the effects of 
such therapies in conjunction with locally and systemically active immunological 
mechanisms. Designing treatment course strategy according to the character of the tumor-
host microenvironment milieu is vital for its long-term efficacy (Formenti, 2010; Pages et al., 
2009; Zitvogel et al., 2008). Today, thirty years after the first modern chemoimmunotherapy 
clinical trials were initiated, the impasse that is melanoma chemoresistance has continued to 
stymie significant, clinically-applicable advancement in this therapeutic field. Given the 
recurring roadblocks of current treatment strategies, traditional methods of chemotherapy 
and immunotherapy use are being radically adjusted to achieve a better overall clinical 
outcome. 
3. Conventional chemoimmunotherapy for the treatment of melanoma 
Immunotherapy can play an important role in the treatment of cancer, and combinations of 
chemotherapy and immunotherapy have been investigated in many clinical trials. Although 
some phase III trials have shown mixed results regarding duration of survival, meta-
analyses have found no improvement in overall survival (Allen et al., 1998; Ives et al., 2007; 
Keilholz et al., 1998; Sasse et al., 2007). Chemoimmunotherapy, or biochemotherapy, has 
been extensively studied in melanoma. Conventional chemoimmunotherapeutic strategies 
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include two major categories. The first category uses cytokines such as IL-2 and/or IFN- in 
combination with chemotherapy. This experimental strategy was not supported by strong 
preclinical evidence and has not been shown to be superior to chemotherapy alone (Atkins 
et al., 2003; Eton et al., 2002; Keilholz et al., 1997, 2005; Rosenberg et al., 1999). The second 
category is a strategy that we have termed ‘immunocentric chemoimmunotherapy’. In this 
approach, the primary or central focus is on immunotherapy, with chemotherapy playing a 
peripheral role in immunomodulation. Using this approach, melanoma patients have been 
successfully treated with non-myeloablative, lymphodepleting chemotherapy and adoptive 
cell transfer with tumor-Ag specific lymphocytes and high dose IL-2 (Dudley et al., 2002, 
2005). Although this strategy is promising, it is not widely applicable to non-melanoma 
cancers due to the difficulty in generating large numbers of tumor-Ag specific tumor-
infiltrating lymphocytes. To date, there have been no studies using chemoimmunotherapy 
that have shown a significant improvement in overall survival (Atkins et al., 2003, 2008; 
Bajetta et al., 2006; Eton et al., 2002; Kielholz et al., 1997, 1998, 2005; Middleton et al., 2007; 
Punt et al., 2006; Ridolofi et al., 2002; Rosenberg et al., 1999), and the development of 
immunotherapy for the treatment of a broad range of cancer types is still lacking. Given the 
proven capacity of many already developed and thoroughly tested, well characterized 
chemotherapeutic agents to have significant, specific and intricate influence over global and 
localized immune response, adjustments to the multitudes of chemoimmunotherapeutic 
strategic fronts are currently being made in anticipation of a clinically relevant 
breakthrough. 
3.1 Cytokines and chemotherapy 
Activated T cells amplify cytokines that are essential for an effective immune response 
(Szabo et al., 2003). These include IL-2, TNF-┙, IL-21 (by activated CD4+ T cells), GM-CSF, 
IFN-┛, and other as yet unidentified cytokines. In addition to their immunomodulatory 
activities, some cytokines can also have direct effects on tumor cells and/or tumor 
vasculature. TNF-┙ is known to induce hemorrhagic necrosis in tumors (Carswell et al., 
1975; Old, 1985) and has also been shown to induce apoptotic and necrotic tumor cell death 
in vitro (Helson et al., 1975; Laster et al., 1988; Rubin et al., 1988; Sugarman et al., 1985). The 
hemorrhagic necrotic effect of TNF-┙ has been shown to be more potent when used in 
combination with chemotherapy in a rat sarcoma model (Manusama et al., 1996). However, 
in these studies, TNF-┙ had no direct activity against tumor cell lines in vitro and 
demonstrated no synergy with chemotherapy, acting instead on the tumor vasculature (van 
Horssen et al., 2006; Watanabe et al., 1988). The IFNs can exert direct effects on the 
proliferation, differentiation, and apoptosis of tumor cells (Chawla-Sarkar et al., 2001, 2003; 
Detjen et al., 2001; Gooch et al, 2000; Pfeffer et al., 1998). However, the response to the IFNs 
varies considerably, depending on the tumor histology, and resistance to the IFNs has been 
reported in several tumor types (Burke et al., 1999; Harvat & Jetten, 1996; Kaplan et al., 1998; 
Phan-Bich et al., 1997).  
Several early-phase trials of cytokines combined with cisplatin-based therapies have shown 
an overall response rate of ~50%, though such responses are of very short duration and 
often complicated by a high degree of systemic toxicity and adverse side effects. Over the 
past 15 years, numerous cisplatin-based cytokine combination regimens have been assessed 
(Atkins et al., 2002, 2003; Atzpodien et al., 2002; Buzaid et al., 1993; Flaherty et al., 2001; 
Legha et al., 1989, 1998; McDermott et al., 2000; Pejcic et al., 2010; Rosenberg et al., 1999, 
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2011; Thompson et al., 1997). Notably, in a phase II trial from 1997, Thompson et al. describe 
the development and utility of an outpatient chemoimmunotherapy treatment regimen of 
monthly cycles of intravenous cisplatin, carmustine, dacarbazine, and tamoxifen plus self-
administered subcutaneous recombinant IL-2 and IFN-┙ for 32 metastatic melanoma 
patients, 30 assessed for clinical response (Thompson et al., 1997). After three months, they 
note a complete response rate of 13% and a 30% partial response, and toxicity was primarily 
restricted to minor fever and nausea with only a few instances of hospitalization for toxicity 
management.  
Rosenberg et al. (Rosenberg et al., 1999) reported in 1999 on their phase II clinical trial 
testing tamoxifen, cisplatin, and dacarbazine in 52 metastatic melanoma patients, while the 
50 patients in the other arm received the same therapy followed by IL-2 and IFN-2b. The 
chemoimmunotherapy arm exhibited 44% total response rate while the chemotherapy arm 
was 27%; however, of the seven complete responders, only three received the cytokines, 
indicating no significant impact of cytokines on complete response, and median duration of 
response was less than six months. Even more disappointing, most of the toxicities were 
reported for the chemoimmunotherapy group. Median duration of survival was 10.7 
months for those receiving cytokines compared to 15.8 months for those without. A regimen 
of concurrent treatment with CVD chemotherapy, IL-2 and low-dose IFN-┙ has shown to be 
better tolerated and more practical than sequential treatment of CVD followed by IL-2/IFN-
┙ (Atkins et al., 2002; Eton et al., 2002; Legha et al., 1998), though randomized phase III trials 
of this CVD/IL-2/IFN-┙ combination show no improvement in response or survival over 
CVD and modified CVD chemotherapy regimens alone (Atkins et al., 2003; Keilholz et al., 
2005). In regard to pre-treatment of a chemoimmunotherapeutic regimen with 
chemotherapy, Punt et al. (Punt et al., 2006) reported on a randomized, phase II clinical trial 
of metastatic melanoma patients receiving either dacarbazine, cisplatin, IFN- and IL-2 or 
the same combination after an initial treatment of two cycles of dacarbazine, finding no 
difference between the two groups in terms of median overall survival.  
O’Day et al. (O’Day et al., 2009) treated 133 chemotherapy-naïve metastatic melanoma 
patients with CVD, decrescendo IL-2, and IFN-┙2b with granulocyte-macrophage colony-
stimulating factor (GM-CSF) cytokine support. Maintenance biotherapy with low-dose IL-2 
and GM-CSF followed by intermittent pulses of decrescendo IL-2 over 12 months was 
provided for those without disease progression. The overall response rate was 44% with 8% 
complete response and 36% partial response. Stable disease was noted for 29% of patients; 
median progression-free survival was 9 months, and median survival was 13.5 months with 
12-month and 24-month survival rates at 57% and 23%, respectively, providing evidence of 
above average long-term survival rates for these patients. Further randomized trials need to 
be carried out.  
A recent multicenter phase II chemoimmunotherapy trial of the Dermatologic Cooperative 
Oncology Group (DeCOG) testing the multi-kinase inhibitor sorafenib in combination with 
pegylated-IFN-┙2b (PEG-IFN-┙2b) in 55 patients with metastatic melanoma resulted in two 
patients with partial response and 14 with stable disease (29.1% disease control rate in 
intent-to-treat population) (Egberts et al., 2011). Median progression-free survival was 2.5 
months, and toxicities were primarily hematological, including one treatment-related 
bleeding complication leading to death. A smaller study of 22 metastatic melanoma patients 
receiving a regimen of CVD with PEG-IFN-┙2b, subcutaneous IL-2 and oral 13-cis-retinoic 
acid, with maintenance biotherapy for those with clinical response after six courses, 
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provided 12 objective responses with seven maintenance-receiving patients having stable 
disease after six months (Recchia et al., 2008). Median progression-free and overall survivals 
were 23.3 and 45.7 months, respectively, with mostly hematological toxicities and 21% of 
patients exhibiting grade 2 autoimmune reactions.  
3.2 Immunocentric chemoimmunotherapy 
Another conventional strategy is one that we have termed ‘immunocentric 
chemoimmunotherapy’. This strategy is an immunotherapy-focused approach which uses 
chemotherapy as an immunomodulator to enhance the effect of cancer vaccines or adoptive 
cell transfer therapy. Based on this approach, recent studies using chemotherapy to prepare 
the host before the infusion of ex vivo activated, melanoma Ag-specific tumor-infiltrating 
lymphocytes and high dose IL-2 have resulted in impressive response rates.  
3.2.1 Cancer vaccines 
Cancer vaccines are promising for their abilities to elicit both humoral (antibody) and 
cellular (T cell) immune responses (Finn, 2008; Schoenfeld et al., 2010) specifically against 
tumor cells, as well as for their minimal side effects and the potential for development of 
immunologic memory allowing for a long-term, durable response to treatment without the 
need for continuous therapy (Yannelli & Wroblewski, 2004). The presence of cell surface 
antigens and receptors, capable of activating a myriad of intracellular biochemical 
pathways, makes possible the development of cancer vaccines with highly stringent criteria 
for target tumor cell selection and may assist in the focused delivery and activity of 
chemotherapeutic agents. The recent FDA-approval of sipuleucel-T (Provenge®; Dendreon 
Inc., Seattle, WA, USA), the first personalized therapeutic cancer vaccine, for the treatment 
of advanced prostate cancer, has opened the doors for novel vaccine development for other 
cancers, contributing to the heightened interest in targeted immune-based study of cancer 
systems.  
Nistico et al. (Nistico et al., 2009) recently reported on their phase I/II pilot study testing 36 
HLA-A2+ disease-free, stage II to IV melanoma patients with standard-dose dacarbazine 
administered one day before vaccination with HLA-A2 restricted melanoma antigen A 
(melan-A/MART-1) and gp100 melanoma peptide vaccination compared with vaccination 
alone. Dacarbazine significantly increased the numbers of peptide-specific CD8+ effector 
memory T cells which recognize and lyse HLA-A2+/melan-A+ tumor cells, indicating the 
enhancement of effective CD8+ T cell recognition of vaccine peptides after treatment with a 
chemotherapy drug in patients with melanoma. Another more recent pilot clinical trial 
(Palermo et al., 2010) by the Nistico group examined the role of dacarbazine again as pre-
treatment to this vaccine therapy, noting a progressive widening of the T cell receptor 
repertoire diversity with concomitant high avidity and tumor reactivity in melan-A–specific 
T cell clones of patients treated with this chemoimmunotherapy and a trend toward longer 
survival. Alternatively, patients receiving vaccine alone exhibited a tendency to narrowing 
the T cell receptor repertoire diversity and a decrease of tumor lytic activity in one patient.  
3.2.2 Adoptive cell transfer 
One of the most exciting avenues for melanoma therapy is adoptive cell transfer of tumor-
reactive T cells harvested from the tumor itself, expanded and activated ex vivo using 
various methods (e.g., high concentrations of IL-2) and then transferred back into the 
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patient. The success of adoptive cell transfer depends on the specificity of T cells for the 
tumor and their ability to survive and proliferate in the environment. Notably, intratumoral 
injection of toll-like receptor agonists were found to enhance the potency of activated 
adoptive cell transfer against a murine model with established subcutaneous melanoma 
tumors, acting to enhance IFN-┛ production and subsequent killing of the now more 
immunogenic tumor cells by adoptively transferred T cells (Amos et al., 2011). Metastatic 
melanoma patients have benefited in certain settings with adoptive cell transfer of tumor-
infiltrating lymphocytes in combination with chemotherapeutic lymphodepletion, with an 
impressive objective response rate of 50-70% (Dudley & Rosenberg, 2007; Gattinoni et al., 
2006; Hershkovitz et al., 2010; Khattar et al., 2009; Rosenberg et al., 2008, 2011; Rosenberg & 
Dudley, 2009). Given the promising results of adoptive cell transfer strategies in melanoma 
and other cancers, many notable contributions are being made toward a more discrete 
understanding of this field.  
During expansion of tumor-infiltrating lymphocytes for infusion, CD8+ T cells are driven to 
differentiate into effector cells, losing key costimulatory molecules such as CD28 and CD27. 
Costimulation with CD137/4-1BB was recently shown to significantly increase lymphocyte 
survival during melanoma adoptive cell transfer and improve the anti-tumor response 
(Hernandez-Chacon et al., 2011). Inozume et al. (Inozume et al., 2010) reported on the 
recovery of function of PD-1 cell surface receptor protein on CD8+ T cells in melanoma 
digests after ex vivo conditioning with IL-2, leading to the production of much more tumor-
specific IFN-┛ compared with PD-1⁻ T cells and the proposal of PD-1 functional operation or 
presence being a capable biomarker for selecting tumor-specific lymphocytes from 
melanomas. As a common practice in adoptive cell transfer prior to infusion of these 
lymphocytes, patient lymphodepletion of T reg and other lymphocytes in competition for 
cytokines allows for a much more potent response to activated tumor-specific T cells 
(Dudley et al., 2002, Wrzesiniski et al., 2010). Adoptive cell transfer with autologous tumor-
infiltrating lymphocytes, conditioned with cyclophosphamide and fludarabine, and IL-2 
tested in 50 metastatic melanoma patients selected to receive either 2-Gy (non-
myeloablative) or 12-Gy (myeloablative) of total body irradiation resulted in response rates 
of 49%, 52% and 72% for patients not receiving radiation and those receiving either 2- or 12-
Gy, respectively (Dudley et al., 2008). The authors note the possibility for increased tumor-
infiltrating lymphocyte activity, proliferation, and/or persistence in the body and at the 
tumor site as a result of rising cytokine availability following irradiation, having seen a 
significant increase of IL-7 and IL-15 in the serum following the myeloablative regimen. This 
trial is part of three whose combined and complete results were recently published by 
Rosenberg et al. (Rosenberg et al. 2011), providing impressive objective response and overall 
survival rates. In a panel of 93 heavily pretreated metastatic melanoma patients (86% with 
visceral metastases and 95% recurring after prior therapy), they found adoptive cell transfer 
of autologous lymphocytes plus high-dose IL-2, administered within one day following a 
lymphodepletion regimen of cyclophosphamide and fludarabine or either 2- or 12-Gy of 
total body irradiation, to produce 52 objective responses (56%) with 20 (22%) complete 
responses, 19 of which lasted a span of three to seven years.  
Other clinical studies have utilized genetically engineered peripheral T cells in place of 
tumor-infiltrating lymphocytes. Due to limitations in generating tumor-specific T cells for 
adoptive cell transfer, Morgan et al. (Morgan et al., 2006) reported on the specific conference 
of tumor recognition by autologous lymphocytes from peripheral blood of 15 metastatic 
melanoma patients using a retrovirus that encodes a T cell receptor recognizing a tumor 
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antigen. Adoptive cell transfer of these transduced cells after lymphodepletion resulted in 
durable engraftment of more than 10% of peripheral blood lymphocyte levels for over two 
months after infusion. In two patients demonstrating objective regression of metastatic 
melanoma lesions, circulating engineered cells were maintained at high levels at one year 
after infusion.  
Such viral T cell receptor engineering is currently being studied for advanced melanoma 
and general (Chinnasamy et al., 2010) cancer therapy by Dr. Steven A. Rosenberg’s group 
and colleagues in The National Cancer Institute’s Surgery Branch (Rosenberg & Dudley, 
2009). Indeed, they have recently described the selective delivery of IL-12, noted for its 
limited immunostimulatory clinical application due to toxicity, into the tumor 
microenvironment upon tumor-Ag recognition by T cell receptors on genetically engineered 
lymphocytes, enhancing in vivo melanoma tumor regression without toxicity (Zhang et al., 
2011). Another recent report from this group describes adoptive cell transfer of autologous T 
cells with a T cell receptor against the NY-ESO-1 cancer/testis antigen, expressed in ~25% of 
patients with melanoma and other epithelial cancers, resulting in an objective response in 
five of 11 patients with NY-ESO-1-expressing tumors, with two complete responses of 
greater than one year (Robbins et al., 2011). 
3.3 Cyclophosphamide for melanoma immunocentric chemoimmunotherapy 
Cyclophosphamide has been an invaluable chemotherapeutic agent in studying 
immunocentric methodology and application. Numerous reports have shown the 
synergistic capabilities of cyclophosphamide in combination with immunotherapeutics, 
describing its ability to induce cytokine expression, type I IFNs and homeostatic 
proliferation of B and T cells and to deplete the T reg population from the tumor site, 
increasing the possibility of CD8+ T cell-mediated targeting and destruction of tumor cells 
(Berd et al., 1986, 1990, 2004; Bracci et al., 2007; Dummer et al., 2002; Ercolini et al., 2005; 
Ghiringhelli et al., 2004; Livingston et al., 1987, 1994; Maine & Mule, 2002; North, 1982; 
Nowak et al., 2006; Proietti et al., 1998; Schiavoni et al., 2000; Turk & Parker, 1982; Zitvogel 
et al., 2008). An important study in 2005 showed non-myeloablative lymphodepleting 
chemotherapy with cyclophosphamide and fludarabine conditioning of tumor-infiltrating 
lymphocytes followed by infusion and subsequent high-dose IL-2 treatment to produce a 
51% overall response rate in 35 metastatic melanoma patients previously having received 
IL-2 therapy, all but one being refractory to IL-2 (Dudley et al., 2005).  
A surge of recent studies have expounded on the role of cyclophosphamide in T reg 
modulation and immune therapies that can take advantage of the T reg depleted tumor 
environment. Combination cyclophosphamide and an agonist antibody against the co-
stimulatory CD4+ Foxp3+ T reg cell receptor OX40 has recently been shown to induce 
apoptosis of the tumor T reg population and induce the influx of CD8+ T cells resulting in a 
potent anti-tumor response in an in vivo B16 melanoma model (Hirschhorn-Cymerman et 
al., 2009). Furthermore, Kohlmeyer et al. (Kohlmeyer et al., 2009) reported chemotherapeutic 
preconditioning with cyclophosphamide prior to adoptive cell transfer and viral vaccination 
followed by adjuvant peritumoral injections of immunostimulatory nucleic acids to be a 
highly effective chemoimmunotherapeutic regimen, resulting in complete regression of 
primary and lung metastatic lesions in the normally adoptive cell transfer-resistant 
genetically engineered Hgf-Cdk4R24C metastatic melanoma mouse model.  
In following the combination of chemotherapy and adoptive cell transfer with immune-
enhancing cytokines, such as IL-2 (Dudley et al., 2002, 2005; Dudley & Rosenberg, 2007; 
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Mihalyo et al., 2004), and the recent characterization of IL-21 with adoptive cell transfer by 
Hinrichs et al. (Hinrichs et al., 2008), another study describes the boosting of immunocentric 
therapeutic efficacy with IL-21 (Petersen et al., 2010), an immune-enhancing cytokine that, 
unlike IL-2, does not support proliferation of activated T reg nor activation-induced cell 
death (Spolski & Leonard, 2008; Waldmann, 2006). As collective data would indicate, IL-21 
likely enhances the T reg-depleting capabilities of cyclophosphamide by abrogating T reg 
development, via  the inhibition of IL-2 secretion, and function (Elsaesser et al., 2009; Fantini 
et al., 2007; Hinrichs et al., 2008; Peluso et al., 2007; Piao et al., 2008; Yi et al., 2009). Mice with 
established tumors, subsequently treated with cyclophosphamide and adoptive cell transfer 
and/or daily injections of IL-21, exhibited better early tumor growth inhibition up to five 
days after the last (day 7) IL-21 injection and increased circulating tumor-specific T cells 
with the IL-21 administration. The authors note the potential for continued tumor growth 
stunting with continued IL-21 injection as well as the importance of timing considerations 
for this particular design (Skak et al., 2009). A similar study by Salem et al. (Salem et al., 
2007) showed a more pronounced effect using peptide vaccination and naïve T cells, 
possibly a more effective option than pre-primed cells for adoptive cell transfer (Hinrichs et 
al., 2008).   
4. Chemocentric chemoimmunotherapy 
We have developed a third strategy for combining chemo- and immunotherapy, termed 
‘chemocentric chemoimmunotherapy’ (Radfar et al., 2009). In this model, chemotherapy plays 
the central effector role, while immunotherapy is used to sensitize the tumor and its 
microenvironment to the cytotoxic effect of chemotherapy. This strategy employs the use of 
nonspecifically activated CD4+ T lymphocytes (aCD4) as a chemosensitizer of tumor cells 
followed by treatment with chemotherapeutic drugs. The rationale for this strategy is based on 
the known ability of activated T cells to secrete multiple cytokines that can regulate 
proliferation and/or apoptosis of tumor cells and the ability of activated T cells to exert direct 
activity on tumor cells through apoptotic pathways such as the Fas/Fas ligand pathway; for 
instance, tumor cell apoptosis is initiated when the Fas ligand, present on activated T cells, 
binds the Fas receptor, present on tumor cells. This model does not depend on Ag-specific 
activation of T cells and is, therefore, potentially applicable to a wide variety of tumor types 
and patients regardless of their HLA status. Indeed, preclinical studies examining the role of 
chemocentric chemoimmunotherapy in melanoma, breast, colon and prostate cancer cell lines 
have shown a dramatic enhancement of induced tumor-cell apoptosis. With the added 
advantage of ease of use and cost effectiveness in the clinic, chemocentric 
chemoimmunotherapy is a promising future methodology that is widely applicable, in terms 
of patient character schema, cost and basic technical utility, in the clinical setting. 
4.1 Chemosensitization with nonspecifically activated CD4+ T cells  
According to conventional wisdom, it is counterintuitive to administer chemotherapy 
immediately after cell therapy because the transferred immune cells will be eliminated by 
chemotherapy. Although this may be true in the setting of conventional immunocentric 
chemoimmunotherapy, where immunotherapy plays the major effector role and 
chemotherapy is used to prepare the host, this approach is rational in the context of 
chemocentric chemoimmunotherapy, where chemotherapy exerts the principal effector 
function and immunotherapy is used transiently for the purpose of presensitization. 
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We have recently demonstrated that presensitization of tumor cells with nonspecifically 
activated CD4+ T cells (aCD4) greatly enhanced the cytotoxic effect of chemotherapy in both 
in vitro and in vivo models (Radfar et al., 2009). This activity was observed for all seven 
tumor cell lines as well as all four chemotherapeutic agents tested. Soluble factors secreted 
from the activated CD4+ T cells were found to be responsible for the observed effect, with 
IFN-┛ playing a major role in the chemosensitization of tumor cells. IFN-┛ by itself, 
however, was consistently inferior to activated CD4+ T cells in the chemosensitization of 
tumor cells. 
For three human metastatic melanoma, two human breast, one prostate and one colon 
cancer cell line, treated with 5-FU, temozolomide (TMZ), carboplatin (Carbo), or paclitaxel, 
chemosensitization with aCD4 had a dramatic impact on tumor cell viability and in vivo 
tumor formation. TMZ, the oral imidazotetrazine derivative of dacarbazine that is also 
capable of crossing the blood-brain barrier, ultimately produces the same dacarbazine 
compound after intake and has been shown in clinical trial to be similarly effective in 
treating metastatic melanoma as dacarbazine (Middleton et al., 2000). Treatment of the A375 
melanoma cell line with TMZ after presensitization with aCD4 resulted in near complete cell 
death, with residual cell viability as low as 5%, compared to 67% viability for cells treated 
with TMZ that were not presensitized with aCD4. Similar study of two more melanoma cell 
lines provided comparable results. Further tests using Carbo, a drug with minimal activity 
against melanoma, resulted in a decrease of melanoma cell viability of ~83% at the optimal 
aCD4 concentration, compared with no change in viability after Carbo treatment alone. 
Non-melanoma cell lines treated with paclitaxel, Carbo or 5-FU all gave similar results. 
Presensitization was found to be mediated in large part via cytokines, principally IFN-┛, and 
not through cell-cell contact. aCD4 supernatants were screened for 13 common Th1 and Th2 
pro- and anti-inflammatory cytokines. IL-1b, IL-5, and IL-12p70 levels were negative or 
minimally expressed. The remaining 10 were tested for in combination against aCD4 alone 
for their chemosensitizing ability, assessed based on viability after TMZ treatment. There 
was no increase in chemosensitizing ability of combination IL-2/-4 over cells without 
cytokine addition, and combinations IL-6/-8 and IL-10/-12p40/-13 produced enhanced 
activity of 7% and 8%, respectively. Combination IFN-┛/TNF-┙/GM-CSF significantly 
enhanced the cytotoxic activity of TMZ by 17%. While most individual cytokines provided 
little to no enhancement of TMZ cytotoxicity, IFN-┛ in combination with other cytokines 
consistently provided the greatest impact on chemosensitization, and IFN-┛ combinations 
showed no improvement over IFN-┛ itself; however, the effects of IFN-┛ by itself or in 
combination lagged the single combination of all 10 tested cytokines. Administration of 
aCD4 alone prior to TMZ treatment as a positive control yielded the best results, showing 
significant enhancement of TMZ cytotoxic cell killing over the 10-cytokine combination. 
Lysates from A375 cells presensitized with aCD4 followed by treatment with TMZ were 
analyzed via a transwell system for cytoplasmic histone-associated DNA fragments as a 
measure of apoptosis. Melanoma cells treated with TMZ alone or aCD4 alone resulted in 
slightly higher levels of DNA fragments, ~49 arbitrary units (AU) and 54 AU, respectively, 
as compared 23 AU for nontreated cells. However, when A375 cells were presensitized with 
aCD4 and treated with TMZ, the level of DNA fragments detected, 1041 AU, was more than 
21-fold over that of the TMZ alone group, 19-fold over the aCD4 alone group, and 45-fold 
over the nontreatment control. In addition, a significantly higher level of caspase-8 activity, 
~2300 RFU, was detected in cells in the experimental group compared with the control 
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groups, i.e., no treatment (524.4 + 3.5 RFU), TMZ treatment only (508.6 + 28.3 RFU), or aCD4 
treatment only (392.7 + 4.0 RFU). A reduction in the relative expression of Bcl-2 protein was 
also detected in A375 cells treated with aCD4 alone or the combination of aCD4 followed by 
TMZ, but not in cells treated with TMZ alone. These data demonstrated that presensitization 
of tumor cells with aCD4 led to a decrease in Bcl-2, and that treatment with aCD4 and TMZ 
together resulted in enhanced caspase-8 activity, resulting in significant reduction in cell 
viability through an increase in apoptosis. The combination of aCD4 and chemotherapy 
yielded dramatic results at 24 hours in viability experiments. To evaluate true pro-apoptotic 
potential of aCD4 presensitization, apoptosis assays were performed at earlier time points, 
12 hours instead of 24 hours after treatment with chemotherapy. For caspase-8 activity, 
chemotherapy treatment was stopped after 5 to 6 hours. Even at these early time points 
when aCD4 alone or chemotherapy alone had no discernable effects, the combination of 
aCD4 and chemotherapy resulted in a dramatic increase in apoptosis and caspase-8 activity. 
Two human tumor xenograft models provided evidence of significant tumor growth delay 
for melanoma and breast cancer after presensitization with aCD4 and subsequent treatment 
with TMZ or paclitaxel, respectively. The melanoma xenograft also displayed significant 
growth inhibition. In the first model, injections of aCD4 were made intratumorally, followed 
48 hours later with intraperitoneal administration of TMZ, to athymic nude mice bearing 
human melanoma A375 xenograft. There was a significantly pronounced delay in tumor 
growth compared with mice receiving no treatment or either treatment alone. Similarly, 
mice bearing aggressive MDA-MB-231 human breast tumors treated with aCD4 followed by 
paclitaxel had significant delay in tumor growth compared with each of the control groups. 
The difference between aCD4 plus paclitaxel versus paclitaxel alone was statistically 
significant. Interestingly, aCD4 alone had a significant growth inhibition effect on the 
melanoma xenograft but not on the breast cancer xenograft. This was consistent with the 
known immuno sensitivity of melanoma compared with other solid tumors. To assess 
toxicity resulting from the experimental treatment, animal weights were measured and 
recorded during the course of the study. No statistically significant difference in weight was 
found between the experimental group and control groups up to day 30 after initiation of 
treatment. 
Some recent studies may help shed light onto the possible mechanisms that underlie the 
dramatic chemosensitizing effect of aCD4. Inflammation and inflammatory cytokines, as 
represented by a mixture of IL-1┚, TNF-┙, and IFN-┛, were shown to generate nitric oxide 
through the induction of nitric oxide synthase, resulting in global inhibition of DNA repair 
activity in cholangiocarcinoma cells (Jaiswal et al., 2000). Perrotta et al. (Perrotta et al., 2007) 
further described chemosensitization through dendritic-cell-mediated intratumoral 
administration of nitric oxide in a B16 mouse melanoma model. Other studies demonstrated 
that IFN-┚ or IL-24 could overcome TMZ resistance in neuroblastoma and melanoma, 
respectively, through down-regulation of the DNA repair enzyme O6-methylguanine-DNA 
methyltransferase expression and activity (Rosati et al., 2008; Zheng et al., 2008). 
Additionally, several recent clinical studies have reported improved response rates and 
survival with salvage chemotherapy in patients who previously received cancer vaccination 
and developed an immune response (Antonia et al., 2006; Arlen et al., 2006; Gribben et al., 
2005; Schlom et al., 2007; Wheeler et al., 2004). Our model may provide a plausible 
mechanism to explain these observations as well as to facilitate further understanding, 
design, and development of improved methods for chemoimmunotherapy in cancer. 
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5. Conclusion 
Despite intense research efforts, scientists are still struggling with the simplest principles of 
tumor cell proliferation, cell cycle kinetics and the genetic basis of malignant transformation 
and tumor progression. In particular, treatment options for melanoma are few, and those 
with metastatic disease have been afforded only meager therapeutic options in the past, 
maintaining a disappointing 15% five-year survival rate. In somewhat of a contradiction, 
melanoma is now at the forefront of targeted and immunological therapeutic study, evident 
by the surging number of relevant publications and the recent addition of ipilimumab to a 
short list of FDA-approved therapies for metastatic melanoma patients. One of the most 
popular and theoretically promising of these directions currently being studied is 
combination chemoimmunotherapy.  
While many chemoimmunotherapeutic regimens have resulted in lackluster responses, our 
novel adaptation of this methodology for melanoma and other cancers, utilizing non-tumor-
specific activation of CD4+ T cells as a chemosensitizer, has provided exciting results. We 
have shown dramatic increases in the efficacies of four functionally unique 
chemotherapeutic drugs in seven cell lines comprising four different cancer types with our 
‘chemocentric chemoimmunotherapeutic’ strategy. After presensitization with aCD4, 
cytotoxicity was greatly enhanced for all chemo drugs, both in vitro and in vivo, against all 
cell types tested. In addition, we recently described the presensitization of tumor cells with 
aCD4 prior to gamma-irradiation to significantly enhance cancer cell growth inhibition 
(Wang et al., 2010). Soluble factors released by aCD4, particularly IFN-┛, were primarily 
responsible for the observed activity, and TNF-┙, though inactive by itself, significantly 
augmented the radiosensitizing activity of IFN-┛.  
Not only are the time and monetary costs of producing non-tumor-specific activated CD4+ T 
cells far and away less than the current standard of activating against a specific set of patient 
tumor cell antigens, but, as our data shows, aCD4 may also be applied in patients with a variety 
of cancer types in synergistic conjunction with the most currently effective and applicable 
chemotherapy for the individual patient. Regardless of the cell line used or its sensitivity or 
resistance to a particular chemotherapeutic drug, in all our tested cases, presensitization with 
aCD4 greatly enhanced the cytotoxicity of the drugs, resulting in near complete cell death. 
Therefore, patients with a typically chemoresistant cancer, such as metastatic melanoma, may 
be able to benefit from enhanced chemotherapeutic efficacy with aCD4 presensitization. 
Additionally, utilization of a much broader range of chemotherapeutic agents may be possible 
for patients who might normally have only a small number of available options, specific for 
their tumor type and physical condition. Patients may thus be able to receive treatment sooner, 
accessing the readily available wealth of well-studied chemotherapeutic drugs without the need 
to await new drug development and testing. To this end, drug selection may ultimately be 
better tailored to patient tolerance, creating a therapeutic strategy with greater anti-tumor 
activity, therefore, less time for development of chemoresistance, and better tolerance which 
will allow more patients to remain on their particular regimen for its appropriate duration. 
Indeed, the utilization of this novel technique may be able to provide a more effective and 
efficient means to combat melanoma and other cancers. 
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